Cardiva Medical has appointed Charles Maroney as president, CEO and member of the its board of directors effective immediately. Mr Maroney succeeds Rick Anderson, who has served as interim CEO since March 2, 2010 and will remain in his role as chairman of the board. Cardiva has also completed a financing that is directed to bring the company's product to market.
Cardiva said that Charles Maroney has over 20 years of medical device experience in successful start up companies. Recently he was CEO of CardioMind, where he joined in 2006 to develop a stent delivery system to treat coronary, neuro and peripheral artery disease.
Prior to CardioMind, he was president and CEO of Coalescent Surgical, a development and sales company focused on blood vessel anastomoses. Colalescent was acquired by Medtronic in 2005.
Before Colalescent, Charles was president and CEO of Prograft Medical, a stent graft technology company. Prograft was purchased by WL Gore and Associates in 1997. Charles started his career in the medical device industry at Target Therapeutics.
Mr Anderson said: “As Cardiva prepares to enter clinical testing for our newest closure product, we sought a leader who had direct experience in helping early stage medical device companies achieve their goals. Charles is an outstanding choice to lead the company into a new era of growth. I am excited about the opportunity at Cardiva and joining the team.”
Cardiva Medical is a privately-held medical device company that designs, develops and commercializes endovascular products which help the body heal itself following percutaneous procedures.